Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials

Sara Pilotto, Massimo Di Maio, Umberto Peretti, Stefania Kinspergher, Matteo Brunelli, Francesco Massari, Isabella Sperduti, Diana Giannarelli, Filippo De Marinis, Giampaolo Tortora, Emilio Bria

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: We performed a sensitivity and meta-regression analysis, cumulating all randomized trials exploring the benefit of afatinib, erlotinib and gefitinib versus chemotherapy in advanced EGFR mutant NSCLC, to investigate the potential role of additional clinico-pathological predictors of TKIs efficacy. Results: With regard to progression-free survival (PFS), a significant interaction according to ethnicity (Asian versus Caucasian versus mixed) and to trial design (retrospective versus prospective EGFR analysis), was found; a trend toward significance with regard to type of drug (gefitinib versus erlotinib versus afatinib) was determined. No statistically significant differences in survival were observed. With regard to response, a significant interaction according to ethnicity, trial design and type of drug, was found. Conclusion: These data, together with a deeper characterization of the molecular background sustaining the oncogenic process, may contribute to create a clinico-pathologic predictive model, aimed to improve the magnitude of benefit expected from the use of targeted agents.

Original languageEnglish
Pages (from-to)135-145
Number of pages11
JournalCritical Reviews in Oncology/Hematology
Volume90
Issue number2
DOIs
Publication statusPublished - 2014

Keywords

  • Afatinib
  • Erlotinib
  • Ethnicity
  • Gefitinib
  • Lung cancer
  • Meta-analysis
  • Trial design

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials'. Together they form a unique fingerprint.

Cite this